|
Dec 1
|
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 8
|
Karyopharm to Participate at Upcoming Investor Conferences
|
|
Nov 6
|
Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study
|
|
Nov 3
|
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript
|
|
Nov 2
|
Karyopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 Million
|
|
Nov 2
|
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)
|
|
Nov 2
|
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
|
|
Jun 28
|
Karyopharm Initiates Pivotal Phase 3 Study of XPO1 Inhibitor Selinexor and Ruxolitinib in JAK Inhibitor (JAKi) Naïve Myelofibrosis
|
|
Apr 27
|
Will Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should Know
|